
Join to view full profile
8140 North MopacBuilding 3, Suite 120Austin, TX 78759
Phone+1 512-349-9889
Fax+1 512-349-9559
Dr. Dubois is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Dermatology, 1988 - 1991
Case Western Reserve University/University Hospitals Cleveland Medical CenterInternship, Internal Medicine, 1987 - 1988
The University of Texas Health Science Center at San AntonioClass of 1987
Certifications & Licensure
TX State Medical License 1995 - 2027
WA State Medical License 1991 - 1994
American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EMA, Modernizing Medicine, Inc., 2016
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
Publications & Presentations
PubMed
- 1 citationsNivobotulinumtoxinA in the Treatment of Lateral Canthal Lines Alone and With Concurrent Treatment of Glabellar Lines.Jean Carruthers, Janet C DuBois, Daniel P Friedmann, Brenda LaTowsky, Melanie D Palm
Dermatologic Surgery. 2026-03-01 - 12 citationsRoflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial.Melinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, Neal Bhatia, Michael Bukhalo
JAMA Dermatology. 2025-07-01 - Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study.Michael Gold, Joel Schlessinger, Greg J Goodman, Steven Dayan, Janet DuBois
Aesthetic Surgery Journal. 2025-05-15
Press Mentions
Promising SK Drug’s Trials Enter Final PhasesMarch 3rd, 2015
Safety of Hydrogen Peroxide Topical Solution 40% and 45% (w/w) in Patients with Seborrheic Keratoses on the Trunk, Extremities, and Face: Results of a Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group StudyAugust 21st, 2019
Vial Launches Innovative Dermatology CRO January 27th, 2022
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









